Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
This safety profile, combined with its healing potential, explains why many athletes and active individuals are turning to BPC-157
PubMed laboratory research record [PMID: 41937527] PubMed record related to this compound for laboratory literature review
The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed
Dosing: Provider-determined (Nasal Spray Troche)
: "" , , : : : 3
It is currently under investigation for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)
US$ 20.16
US$ 22.45
.png)
US$ 20.86
US$ 21.42
US$ 22.62
US$ 20.92
